Kairos Ventures is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Beverly Hills. The company was established in North America in United States.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Kairos Ventures, startups are often financed by Tech Coast Angels, Foundation Venture Capital Group, The Angels' Forum. The meaningful sponsors for the fund in investment in the same round are Spruce Capital Partners, Penn Medicine Co-Investment Fund, DEFTA Partners. In the next rounds fund is usually obtained by Spruce Capital Partners, BASF Venture Capital, Vesalius Biocapital Partners.
This organization was formed by James Demetriades. The overall number of key employees were 3.
Speaking about the real fund results, this VC is 25 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. This Kairos Ventures works on 26 percentage points less the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2015. The fund is generally included in 7-12 deals every year.
Among the most popular portfolio startups of the fund, we may highlight Axial Biotherapeutics, Provivi, Neuro-Bio. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Renewable Energy, Health Care.
Related Funds
Fund Name | Location |
AAC Capital Partners | Amsterdam, Noord-Holland, The Netherlands |
Alliance Trust | Dundee, Dundee City, United Kingdom |
Center for the Advancement of Science in Space | Florida, Merritt Island, United States |
CITIC M&A Fund | Beijing, Beijing, China |
EduLab | Japan, Tokyo |
Gongdao Chuangxin | Beijing, Beijing, China |
Hongzhao Fund | China, Futian District, Guangdong Province |
Landmark Partners | Connecticut, Simsbury, United States |
Liguo Chuangjing | Beijing, Beijing, China |
Macnica Ventures | - |
MISAWA HOMES | Japan, Tokyo |
Morgan Noble | District of Columbia, United States, Washington |
NE Angels | - |
Nutty Capital Venture | China, Hong Kong, Hong Kong Island |
Share Capital Partners | China, Guangdong, Shenzhen |
StarterStudio | - |
The Crawford Group | Missouri, St Louis, United States |
UltimateVC | Cyprus, Limassol |
Virtue Inno Valley | Beijing, China, Haidian |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Vivodyne | $38M | 22 Nov 2023 | Philadelphia, Pennsylvania, United States | ||
PteroDynamics | $7M | 28 Feb 2023 | Ventura, California, United States | ||
Tulu | $3M | 13 Apr 2021 | New York, New York, United States | ||
Vivodyne | $2M | 11 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
AetherTouch | 03 Mar 2021 | - | |||
Novosteo | $5M | 13 Jan 2021 | Pennsylvania, United States | ||
$45M | 22 Dec 2020 | Santa Monica, California, United States | |||
PteroDynamics | 01 Jan 2020 | Ventura, California, United States | |||
$7M | 23 Dec 2019 | Los Angeles, California, United States |
– Novosteo Closes $5.5m in Series A Financing.
– The company raised $5.5m in Series A financing.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Research Bridge Partners announced that one of its portfolio companies, Novosteo, Inc., closed $5.5m in Series A financing to further development of the first-ever targeted bone anabolic agent NOV004.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Novosteo, Inc.’s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Vivodyne | $38M | 22 Nov 2023 | Philadelphia, Pennsylvania, United States | ||
PteroDynamics | $7M | 28 Feb 2023 | Ventura, California, United States | ||
Tulu | $3M | 13 Apr 2021 | New York, New York, United States | ||
Vivodyne | $2M | 11 Mar 2021 | Philadelphia, Pennsylvania, United States | ||
AetherTouch | 03 Mar 2021 | - | |||
Novosteo | $5M | 13 Jan 2021 | Pennsylvania, United States | ||
$45M | 22 Dec 2020 | Santa Monica, California, United States | |||
PteroDynamics | 01 Jan 2020 | Ventura, California, United States | |||
$7M | 23 Dec 2019 | Los Angeles, California, United States |